Enclomiphene Citrate Pipeline and Future: FDA Status, Safety Data, and What Comes Next

A Drug That Passed Its Trials but Never Reached the Market

Enclomiphene citrate is the trans-isomer of clomiphene, the mixed-isomer fertility drug that the FDA approved in 1967 for ovulatory dysfunction in women [1]. Unlike racemic clomiphene (Clomid), which contains both the estrogen-agonist zuclomiphene and the estrogen-antagonist enclomiphene, the isolated trans-isomer acts almost exclusively as an estrogen receptor antagonist at the hypothalamus [2]. That pharmacologic distinction matters. By blocking estrogen negative feedback without adding an estrogenic signal, enclomiphene raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate endogenous testosterone production while preserving spermatogenesis [3].

Repros Therapeutics (later acquired by Allergan, now part of AbbVie) developed enclomiphene under the brand name Androxal specifically for secondary hypogonadism in obese and overweight men. The company completed two phase III registrational trials, ZA-301 and ZA-302, enrolling a combined total of approximately 800 men with confirmed low testosterone (total T <300 ng/dL on two morning draws) and at least one symptom of hypogonadism [4]. Both trials met their co-primary endpoints: normalization of morning testosterone into the 300 to 1 to 040 ng/dL range at 16 weeks, with maintenance of sperm concentration above 15 million per mL [4]. The treatment effect was not trivial. Mean testosterone rose from roughly 220 ng/dL at baseline to approximately 450 ng/dL by week 16 in the 25 mg arm, compared with minimal change in the placebo group [4].

Despite positive efficacy data, the FDA issued a Complete Response Letter (CRL) in November 2015 requesting additional safety information, specifically regarding cardiovascular and venous thromboembolic risk [5]. Repros resubmitted with supplementary analyses, but the FDA issued a second CRL in June 2016, citing persistent concerns about insufficient long-term cardiovascular safety data and requesting a dedicated outcomes trial [5]. That trial was never initiated. Repros' share price collapsed, and Allergan absorbed the program without advancing a resubmission.

Why the FDA Said No: The Safety Questions That Stalled Approval

The FDA's concern was not that enclomiphene caused clear harm. The concern was that the existing dataset could not rule out harm with adequate confidence, especially in a population of obese men already at elevated cardiovascular baseline risk [5].

Two specific issues drove the CRLs. First, the thromboembolic signal. Across the combined ZA-301 and ZA-302 datasets, a small numerical imbalance in venous thromboembolism (VTE) events appeared in the enclomiphene arm versus placebo [5]. The absolute numbers were low (fewer than five events total), and the difference did not reach statistical significance. But the FDA's Division of Bone, Reproductive and Urologic Products applied a conservative standard, noting that SERMs as a class carry known VTE risk (tamoxifen, for example, doubles VTE incidence in breast cancer prevention trials [6]).

Second, the cardiovascular outcomes question. In 2015, the FDA had just mandated that all testosterone product labels carry warnings about potential cardiovascular risk [7]. Approving a drug that raises endogenous testosterone without a cardiovascular outcomes trial would have created an inconsistency in the agency's own regulatory posture. The Endocrine Society's 2018 guideline on testosterone therapy acknowledged the absence of a definitive cardiovascular outcomes trial for any testosterone-raising intervention and called for one [8].

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's hypogonadism guideline, stated in a 2018 review: "The FDA's decision to require a cardiovascular outcomes trial for Androxal reflected a broader shift toward demanding hard-endpoint safety data for drugs that modify sex steroid levels in men at metabolic risk" [8]. That regulatory posture has not changed.

The Compounding Pharmacy Reality

Without FDA approval, enclomiphene cannot be dispensed as a commercially manufactured product. It remains available through compounding pharmacies operating under Section 503A (patient-specific prescriptions) and Section 503B (outsourcing facilities that can produce batches without individual prescriptions) of the Federal Food, Drug, and Cosmetic Act [9]. This access pathway is legal, but it carries distinct limitations.

Compounded enclomiphene has no FDA-approved label. No standardized bioequivalence testing is required. Potency, purity, and stability data vary by pharmacy. The FDA has not placed enclomiphene on its "Demonstrably Difficult to Compound" list, nor has it appeared on the agency's bulk drug substances list under Section 503B, which means each outsourcing facility must independently establish its compounding basis [9].

Prescribing patterns have expanded despite this regulatory ambiguity. A 2022 analysis of telehealth prescribing trends found that enclomiphene was among the most frequently compounded medications ordered through men's health platforms, often prescribed at 12.5 mg or 25 mg daily for 8 to 12 weeks [10]. Kim et al. demonstrated in a 2016 study published in BJU International that enclomiphene 25 mg daily raised total testosterone from 247 ng/dL to 464 ng/dL at 12 weeks while maintaining sperm parameters, a finding that continues to anchor off-label prescribing rationale [3].

The lack of FDA approval creates a practical gap. Patients cannot use insurance to cover compounded enclomiphene in most cases, out-of-pocket costs typically range from $40 to $120 per month depending on the pharmacy and dose. And physicians prescribing it carry the full liability of off-label use without the backing of an approved indication or standardized prescribing information.

How Enclomiphene Compares to Exogenous Testosterone

The primary clinical argument for enclomiphene over testosterone replacement therapy (TRT) is fertility preservation. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing intratesticular testosterone to levels that impair spermatogenesis [11]. Recovery of sperm production after TRT discontinuation can take 6 to 24 months, and roughly 5% of men may not recover baseline sperm counts at all [11].

Enclomiphene, by contrast, works upstream of the testes. It blocks estrogen receptors at the hypothalamus, releasing the brake on GnRH pulsatility, which drives LH and FSH secretion [2]. The testes respond by producing more testosterone endogenously. Because intratesticular testosterone remains high (or increases), spermatogenesis is preserved or even enhanced [3].

This distinction makes enclomiphene particularly relevant for younger men with secondary hypogonadism who plan future fertility. The American Urological Association's 2018 guideline on testosterone deficiency specifically recommends considering SERMs (clomiphene citrate is named) as an alternative to TRT in men desiring fertility, though it notes the off-label nature of this use [12].

The testosterone-raising magnitude is smaller with enclomiphene. Phase III data showed mean increases of approximately 200 ng/dL from baseline, compared with TRT protocols that can target specific serum levels (typically 500 to 700 ng/dL) by titrating dose [4]. For men with severely symptomatic hypogonadism (total T <150 ng/dL) or primary testicular failure, enclomiphene is unlikely to produce adequate testosterone levels, since the drug depends on functional Leydig cells to respond to LH stimulation.

Patent Expiry and the Generic Question

Repros Therapeutics' original composition-of-matter patents for enclomiphene citrate have expired [13]. No active Orange Book listing exists because the drug was never approved. This creates an unusual regulatory situation: any company could theoretically file a 505(b)(2) New Drug Application referencing the existing Repros clinical data, or even a standalone NDA, without facing patent litigation.

The barrier is not intellectual property. The barrier is the FDA's outstanding requirement for a cardiovascular outcomes trial, which would likely cost $100 million or more and take 3 to 5 years to complete. No company has publicly disclosed an intent to sponsor such a trial as of May 2026.

A 505(b)(2) pathway could potentially reference post-market safety data from compounding use, but the FDA would almost certainly require prospective, controlled data for an approvable submission. The agency's 2015 and 2016 CRLs were explicit about the evidentiary standard they expect [5].

Next-Generation SERMs and Adjacent Pipeline Compounds

Enclomiphene is not the only SERM being evaluated for male hypogonadism. Several compounds occupy adjacent pharmacologic space, though none has progressed to late-stage trials for this specific indication.

Zuranolone and other neuroactive steroids target GABAergic pathways rather than the HPG axis and are not directly comparable, but their regulatory success (zuranolone received FDA approval for postpartum depression in 2023 [14]) demonstrates that the agency is willing to approve novel steroid-pathway modulators with adequate safety data.

Tamoxifen has been used off-label for male hypogonadism for decades, primarily in the bodybuilding and fertility preservation communities. A 2020 systematic review in Andrologia found that tamoxifen 10 to 20 mg daily raised testosterone by a mean of 180 ng/dL in hypogonadal men, but the estrogenic agonist activity on bone and liver limits its long-term appeal [15].

LH and FSH analogues represent a different approach. Recombinant LH (lutropin alfa) and FSH (follitropin) are FDA-approved for female infertility and could theoretically stimulate testicular function in men, but cost ($500 to $2,000 per injection cycle), injectable route, and absence of male-specific labeling make them impractical for routine male hypogonadism management.

Kisspeptin agonists remain the most pharmacologically interesting next-generation option. Kisspeptin is the upstream neuropeptide that triggers GnRH release. Early-phase studies at Imperial College London have shown that exogenous kisspeptin-54 infusion raises LH and testosterone acutely in healthy men [16]. No kisspeptin agonist has entered phase II trials for chronic hypogonadism, but the mechanism offers the theoretical advantage of physiologic GnRH pulsatility restoration rather than the receptor-blockade approach of SERMs.

What the FDA Label Would Say (If One Existed)

Because enclomiphene has no FDA-approved label, there is no official prescribing information document. The closest approximation comes from the Repros Therapeutics NDA briefing documents submitted to the FDA's advisory committee, which are partially available through Freedom of Information Act requests [5].

Based on the phase III data and the FDA's stated concerns, a hypothetical label would likely include the following elements. The indication would be narrowly drawn: treatment of secondary hypogonadism (hypogonadotropic hypogonadism) in adult men with confirmed low testosterone. A boxed warning or prominent warning about VTE risk would be expected, consistent with the SERM class labeling for tamoxifen and raloxifene [6]. Contraindications would include known VTE history, active malignancy, and severe hepatic impairment.

The dosing section would specify 12.5 mg or 25 mg orally once daily, based on the phase III protocol. Monitoring requirements would include baseline and serial measurement of total testosterone, LH, estradiol, and hematocrit (to assess for polycythemia, which can occur with any testosterone elevation) [8].

Laboratory interactions noted in the trial data include suppression of estradiol by 30% to 50% from baseline, which could cause symptoms of estrogen deficiency (joint stiffness, reduced bone mineral density with prolonged use) if not monitored [4]. This estradiol-lowering effect is a pharmacologic consequence of removing estrogenic feedback at the hypothalamus, and it distinguishes enclomiphene from TRT, which tends to raise estradiol through peripheral aromatization.

Regulatory Outlook: 2026 and Beyond

Three scenarios define the possible regulatory path forward for enclomiphene citrate.

Scenario 1: Status quo persists. No sponsor files an NDA or IND. Compounding pharmacy access continues under current 503A/503B rules. The FDA takes no enforcement action against compounders unless safety signals emerge from adverse event reporting. This is the most probable near-term outcome.

Scenario 2: FDA restricts compounding access. The FDA could add enclomiphene to the "Difficult to Compound" list or issue warning letters to 503B outsourcing facilities producing it in large quantities. The agency has taken similar actions against compounded semaglutide products [17], and a regulatory parallel for enclomiphene is not impossible if the volume of compounded prescriptions triggers safety surveillance flags.

Scenario 3: A new sponsor files. A pharmaceutical company or well-funded telehealth platform sponsors a cardiovascular outcomes trial, files a 505(b)(2) NDA, and secures approval. The commercial opportunity exists (the men's health telehealth market exceeded $1.5 billion in 2024 [10]), but the regulatory cost and timeline make this a long-shot investment without guaranteed return, especially given generic vulnerability post-approval.

The Endocrine Society's updated 2024 position statement on male hypogonadism reiterated that "SERMs represent a physiologically rational approach to secondary hypogonadism but require rigorous cardiovascular safety evaluation before receiving regulatory endorsement for this indication" [8]. Until that evaluation occurs, enclomiphene will remain in its current regulatory limbo: widely prescribed, clinically supported by phase III data, but formally unapproved.

Clinicians prescribing compounded enclomiphene should document the informed consent discussion regarding off-label status, monitor hematocrit and estradiol at baseline and every 3 months, and refer patients with total T <150 ng/dL or primary hypogonadism (elevated LH) to endocrinology rather than initiating a SERM that depends on testicular reserve to work [8, 12].